Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors
jRCT2080223309Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenigacestat in Nonhematologic neoplasms and solid tumor, sponsored by Eli Lilly and Company. Started Sep 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080223309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223309.